These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 35292162)

  • 21. Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial.
    Chen GL; Li XF; Dai XH; Li N; Cheng ML; Huang Z; Shen J; Ge YH; Shen ZW; Deng YQ; Yang SY; Zhao H; Zhang NN; Zhang YF; Wei L; Wu KQ; Zhu MF; Peng CG; Jiang Q; Cao SC; Li YH; Zhao DH; Wu XH; Ni L; Shen HH; Dong C; Ying B; Sheng GP; Qin CF; Gao HN; Li LJ
    Lancet Microbe; 2022 Mar; 3(3):e193-e202. PubMed ID: 35098177
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Primary Factors Influencing the Decision to Vaccinate against COVID-19 in the United States: A Pre-Vaccine Analysis.
    Varol S; Catma S; Reindl D; Serieux E
    Int J Environ Res Public Health; 2022 Jan; 19(3):. PubMed ID: 35162050
    [TBL] [Abstract][Full Text] [Related]  

  • 23. COVID-19 Coronavirus Vaccine Design Using Reverse Vaccinology and Machine Learning.
    Ong E; Wong MU; Huffman A; He Y
    Front Immunol; 2020; 11():1581. PubMed ID: 32719684
    [TBL] [Abstract][Full Text] [Related]  

  • 24. COVID-19 vaccination: Recommendations for management of patients with allergy or immune-based diseases.
    Peter J
    S Afr Med J; 2021 Feb; 111(4):291-294. PubMed ID: 33944757
    [TBL] [Abstract][Full Text] [Related]  

  • 25. COVID-19 Pandemic and Vaccines Update on Challenges and Resolutions.
    Khan WH; Hashmi Z; Goel A; Ahmad R; Gupta K; Khan N; Alam I; Ahmed F; Ansari MA
    Front Cell Infect Microbiol; 2021; 11():690621. PubMed ID: 34568087
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Rapid Development and Early Success of Covid 19 Vaccines Have Raised Hopes for Accelerating the Cancer Treatment Mechanism.
    Amanpour S
    Arch Razi Inst; 2021 Mar; 76(1):1-6. PubMed ID: 33818952
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A comparison between SARS-CoV-1 and SARS-CoV2: an update on current COVID-19 vaccines.
    Abdolmaleki G; Taheri MA; Paridehpour S; Mohammadi NM; Tabatabaei YA; Mousavi T; Amin M
    Daru; 2022 Dec; 30(2):379-406. PubMed ID: 36050585
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Review of Current Vaccine Development Strategies to Prevent Coronavirus Disease 2019 (COVID-19).
    Bennet BM; Wolf J; Laureano R; Sellers RS
    Toxicol Pathol; 2020 Oct; 48(7):800-809. PubMed ID: 32926660
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Double-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of treating Healthcare Professionals with the Adsorbed COVID-19 (Inactivated) Vaccine Manufactured by Sinovac - PROFISCOV: A structured summary of a study protocol for a randomised controlled trial.
    Palacios R; Patiño EG; de Oliveira Piorelli R; Conde MTRP; Batista AP; Zeng G; Xin Q; Kallas EG; Flores J; Ockenhouse CF; Gast C
    Trials; 2020 Oct; 21(1):853. PubMed ID: 33059771
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [The organizational aspects of security support of participants of clinical testing of vaccine "Gam-COVID-Vac"].
    Naygovzina NB; Khabriev RU; Krasheninnikov AE; Matveev AV
    Probl Sotsialnoi Gig Zdravookhranenniiai Istor Med; 2021 Jan; 29(1):5-13. PubMed ID: 33591649
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The COVID-19 Vaccine: Trust, doubt, and hope for a future beyond the pandemic in Germany.
    Fiske A; Schönweitz F; Eichinger J; Zimmermann B; Hangel N; Sierawska A; McLennan S; Buyx A
    PLoS One; 2022; 17(4):e0266659. PubMed ID: 35390085
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months.
    Thomas SJ; Moreira ED; Kitchin N; Absalon J; Gurtman A; Lockhart S; Perez JL; Pérez Marc G; Polack FP; Zerbini C; Bailey R; Swanson KA; Xu X; Roychoudhury S; Koury K; Bouguermouh S; Kalina WV; Cooper D; Frenck RW; Hammitt LL; Türeci Ö; Nell H; Schaefer A; Ünal S; Yang Q; Liberator P; Tresnan DB; Mather S; Dormitzer PR; Şahin U; Gruber WC; Jansen KU;
    N Engl J Med; 2021 Nov; 385(19):1761-1773. PubMed ID: 34525277
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Development of SARS-CoV-2 vaccines: challenges, risks, and the way forward.
    Vashishtha VM; Kumar P
    Hum Vaccin Immunother; 2021 Jun; 17(6):1635-1649. PubMed ID: 33270478
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The COVID-19 vaccine development: A pandemic paradigm.
    Carneiro DC; Sousa JD; Monteiro-Cunha JP
    Virus Res; 2021 Aug; 301():198454. PubMed ID: 34015363
    [TBL] [Abstract][Full Text] [Related]  

  • 35. SARS-CoV-2: Unique Challenges of the Virus and Vaccines.
    Mahmoodpoor A; Sanaie S; Samadi P; Yousefi M; Nader ND
    Immunol Invest; 2021 Oct; 50(7):802-809. PubMed ID: 34109900
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Consensus summary report for CEPI/BC March 12-13, 2020 meeting: Assessment of risk of disease enhancement with COVID-19 vaccines.
    Lambert PH; Ambrosino DM; Andersen SR; Baric RS; Black SB; Chen RT; Dekker CL; Didierlaurent AM; Graham BS; Martin SD; Molrine DC; Perlman S; Picard-Fraser PA; Pollard AJ; Qin C; Subbarao K; Cramer JP
    Vaccine; 2020 Jun; 38(31):4783-4791. PubMed ID: 32507409
    [TBL] [Abstract][Full Text] [Related]  

  • 37. COVID-19 vaccine update: vaccine effectiveness, SARS-CoV-2 variants, boosters, adverse effects, and immune correlates of protection.
    Chi WY; Li YD; Huang HC; Chan TEH; Chow SY; Su JH; Ferrall L; Hung CF; Wu TC
    J Biomed Sci; 2022 Oct; 29(1):82. PubMed ID: 36243868
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CoronaVac: A review of efficacy, safety, and immunogenicity of the inactivated vaccine against SARS-CoV-2.
    Jin L; Li Z; Zhang X; Li J; Zhu F
    Hum Vaccin Immunother; 2022 Nov; 18(6):2096970. PubMed ID: 35878789
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Potential Therapeutic Targets and Vaccine Development for SARS-CoV-2/COVID-19 Pandemic Management: A Review on the Recent Update.
    Anand U; Jakhmola S; Indari O; Jha HC; Chen ZS; Tripathi V; Pérez de la Lastra JM
    Front Immunol; 2021; 12():658519. PubMed ID: 34276652
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Scrutinizing the SARS-CoV-2 protein information for designing an effective vaccine encompassing both the T-cell and B-cell epitopes.
    Jain N; Shankar U; Majee P; Kumar A
    Infect Genet Evol; 2021 Jan; 87():104648. PubMed ID: 33264668
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.